914780-95-3

Usage

Chemical structure

A complex organic compound with a unique structure, consisting of a spiro-linked system of two rings (one containing oxygen atoms and the other containing nitrogen atoms).

Synthesis

Synthesized through a combination of various chemical reactions and processes.

Natural occurrence

Not commonly found in nature.

Applications

Primarily used for research and experimental purposes in the field of organic chemistry.

Reactivity

Known for its high reactivity.

Potential uses

Has potential applications in the medicinal and pharmaceutical industries.

Ongoing research

Its precise uses and properties are still being explored by scientists and researchers.

Upstream product

• 1246508-12-2 ethyl 2-(8-(nitromethyl)-1,4-dioxaspiro-[4,5]-decan-8-yl-acetate) 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 172270-85-8 8-(methoxyformylmethylene)-1,4-dioxaspiro[4.5]decane 
• 914780-94-2 methyl [8-(nitromethyl)-1,4-dioxaspiro[4.5]dec-8-yl]acetate 
• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 

Downstream Products

• 914780-96-4 2-azaspiro[4.5]decane-3,8-dione 
• 1246508-13-3 10-benzyl-1,4-dioxa-10-azadispiro[4.2.4⁸.2⁵]tetradecan-11-one 
• 1272758-17-4 tert-butyl 8-oxo-2-azaspiro[4.5]decane-2-carboxylate 
• 1246508-14-4 10-benzyl-1,4-dioxa-10-azadispiro[4.2.4⁸.2⁵]tetradecane 

Relevant academic research and scientific papers

FACTOR XIIa INHIBITORS

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted ceteroary compound as well as a composition and a purpose thereof. The substituted ceteroary compound is a compound shown as a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the pharmaceutically acceptable salt of the compound shown as the formula (I) and is used for regulating diseases or disorders mediated by one kind or various kinds of Janus kinase activities. The invention also provides a medicine composition containing the compound and a method of treating or alleviating the disease or disorder degree of a patient by inhibiting the Janus kinase activity.

SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.

PYRIMIDINE PYRAZOLYL DERIVATIVES

The present invention provides compounds of Formula (I) for the treatment of cancer, rheumatoid arthritis and other diseases (I).

Substituted Spiro-amide Compounds

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula (I) : or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, Y1, and Z are as defined herein, are useful for treating flavivi?dae viral infections Said viral infection is Hepatitis C virus (HCV), bovme viral diarrhea virus (BVDV), hog cholera virus, dengue fever virus, Japanese encephalitis virus or yellow fever virus